

SERUM CA 125 AS A PROGNOSTIC TUMOR MARKER FOR NON-HODGKIN'S LYMPHOMA

Thesis

*Submitted for Partial Fulfillment of Master Degree
In Clinical and Chemical Pathology*

By

Mohamed Moustafa Ahmed Abdel Hamid

M.B., B.CH

Ain Shams University

Supervised by

Professor Azza El-Sayed Hashem

Professor of Clinical and Chemical pathology

Faculty of Medicine- Ain Shams University

Professor Amal Abdel Hamid Mohamed

Professor of Clinical and Chemical pathology

Faculty of Medicine- Ain Shams University

**Faculty of Medicine
Ain Shams University**

2012



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا

عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

()



Acknowledgement

*First of all, all gratitude is due to **Allah** for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.*

*Really I can hardly find the words to express my sincere gratitude to **Prof. Dr. Azza El-Sayed Hashem** Professor of Clinical and Chemical Pathology, faculty of medicine, Ain Shams University, for her supervision, continuous help, encouragement throughout this work and great effort she has done in the meticulous revision of the whole work. It is a great honor to work under her guidance and supervision.*

*I am also grateful to **Prof. Dr. Amal Abdel Hamid Mohamed** Professor of Clinical and Chemical Pathology, faculty of medicine, Ain Shams University for her guidance, continuous assistance, sincere supervision, great support, kind advices and valuable suggestion.*

*I would like also to express my sincere appreciation and gratitude to **Prof. Dr. Aml Moustafa El-Afifi** Professor of Clinical Haematology, faculty of medicine, Ain Shams University, for her continuous help and support.*



*I would like to dedicate this thesis to my **Father**,
my **Mother** and my **Sister**; to them I will never find
adequate words to express my gratitude.*

LIST OF CONTENTS

<i>Title</i>	<i>Page</i>
<i>Introduction</i>	<i>1</i>
<i>Aim of the work</i>	<i>2</i>
<i>Chapter I: Non- Hodgkin's lymphoma</i>	<i>3</i>
Definition	3
Epidemiology	3
Etiology	5
Differentiation of healthy lymphocytes and pathogenesis of lymphoma	7
Classification	10
Staging of non-Hodgkin's Lymphoma	12
Factors that affect prognosis for non- Hodgkin's lymphoma	14
Clinical features of patients with non-Hodgkin's lymphoma	18
Pathological types of non-Hodgkin's lymphoma	20
Precursor B-Cell Lymphoblastic Lymphoma (Pre- B CLL)	20
Follicular Lymphoma (FL)	20
Mantle Cell Lymphoma (MCL)	23
Small Lymphocytic Lymphoma / Chronic Lymphocytic Leukemia (SLL/CLL)	25
Extranodal Marginal Zone Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)	27
Splenic Marginal Zone Lymphoma (SMZL)	28
Nodal Marginal Zone Lymphoma (NMZL)	29
Lymphoplasmacytic Lymphoma (LPL)	29
Diffuse Large B-Cell Lymphoma (DLBCL)	32
Burkitt's Lymphoma (BL)	34
Precursor T-Lymphoblastic Lymphoma/Leukemia	36

<i>Title</i>	<i>Page</i>
Adult T-Cell Leukemia/Lymphoma	37
Mycosis Fungoides (MF)	39
Sézary Syndrome (SS)	40
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type	41
Angioimmunoblastic T-Cell Lymphoma	42
Peripheral T-Cell Lymphoma, Unspecified	43
Anaplastic Large-Cell Lymphoma (ALCL)	44
Complications of non-Hodgkin's lymphoma	47
Principles of evaluation of a patient with non- Hodgkin's lymphoma	48
Treatment response and follow-up	53
Detection of minimal disease	54
 Chapter II: Tumor markers.....	56
Serum markers as an effective tool for diagnosis and monitoring of cancer	57
Functional Classification of Tumor Markers	59
Clinical Applications of serum tumor markers	60
Guidelines for the use of tumor markers	68
Examples of individual tumor markers	70
α -Fetoprotein	70
Angiogenic Factors	71
β 2-Microglobulin	72
CA 15-3	73
CA 19-9	74
CA 125	76
Calcitonin	77
Carcinoembryonic Antigen	77
CA 72-4	78
Chromogranin A	79
Cytokeratin 19 Fragment	80

<i>Title</i>	<i>Page</i>
Human Chorionic Gonadotropin (HCG)	81
P53	83
Serum Prostate-Specific Antigen (PSA)	84
Parathyroid Hormone-Related Peptide (PTH-RP)	86
Conclusions and directions for the future	87
Serum Proteomics in the detection of cancer	88
 <i>Chapter III: CA-125 in non-hematological and hematological malignancies</i>	 <i>89</i>
Structure and function of CA 125 molecule	90
Different benign and malignant conditions with elevated CA 125 levels	92
Value of CA 125 expression in different non- hematological malignancies	93
CA-125 progression in ovarian cancer	93
Value of combination of TSGF and CA-125 in diagnosis of endometrial carcinoma	99
Value of CA 125 expression in different hematological malignancies	100
Increased CA 125 serum levels in patients with advanced acute leukemia with serosal involvement.....	100
CA 125 expression in Chronic lymphocytic leukemia (CLL)	100
Significance of elevated CA 125 levels in IgE myeloma	101
Significance of elevated levels of CA 125 in patients with non- Hodgkin's lymphoma (NHL)	103

<i>Title</i>	<i>Page</i>
<i>Subjects and Methods</i>	<i>106</i>
<i>Results</i>	<i>112</i>
<i>Discussion</i>	<i>143</i>
<i>Conclusion</i>	<i>151</i>
<i>Recommendations</i>	<i>152</i>
<i>Summary</i>	<i>153</i>
<i>References</i>	<i>156</i>
<i>Arabic summary</i>	

List of abbreviations

ABC	Activated B-cell
AFP	α -fetoprotein
AIDS	Acquired immunodeficiency syndrome
ALCL	Anaplastic Large-Cell Lymphoma
ALK	Anaplastic lymphoma kinase
ALP	Alkaline phosphatase
ASCO	American society of clinical oncology
Bcl	B cell leukaemia/lymphoma
β HCG	β chain of human chorionic gonadotropin
β_2 m	β_2 microglobulin
bFGF	basic fibroblast growth factor
BL	Burkitt's lymphoma
BM	Bone marrow
BPH	Benign prostatic hypertrophy
CA	Cancer antigen or Carbohydrate antigen
CBC	Complete blood count
CD	Cluster of differentiation
CDR	Complementarity determining region
CEA	Carcinoembryonic antigen
CHOP	Cyclophosphamide, Hydroxyrubicin, Oncovin, Prednisilone
CLL	Chronic Lymphocytic Leukaemia
CML	Chronic Myeloid Leukaemia
CNS	Central nervous system
CT	Computed tomography
CYFRA 21-1	Cytokeratin subunit 19
DCs	Dendritic cells
DHEA	Dihydroepiandrosterone
DIC	Disseminated intravascular coagulation
DLBCL	Diffuse Large B-Cell Lymphoma
DNA	Deoxyribonucleic acid
DRE	Digital rectal examination
EAU	European association of urology
EBV	Epstein Barr virus
ECD	Extracellular domain

Eff	Efficacy
ERM	Ezrin, Radixin and Moesin
FDC	Follicular dendritic cell
FDG	18-fluoro-2-deoxyglucose
FL	Follicular lymphoma
FLIPI	Follicular Lymphoma International Prognostic Index
FN	False negative
FP	False positive
GC	Germinal center
GCB	Germinal center B-cell
GCTs	Germ cell tumors
GI	Gastrointestinal
Hb	Haemoglobin
HCC	Hepatocellular carcinoma
HCG	Human chorionic gonadotropin
HCs	Hematopoietic cancers
HHV-8	Human herpes virus 8
HIV	Human Immunodeficiency Virus
hK	human glandular kallikrein
HPFs	High-power fields
H. pylori	Helicobacter pylori
HS	Highly significant
HTLV-I	Human T-cell lymphotropic virus type I
Ig	Immunoglobulin
IGH	Immunoglobulin heavy chain
IL-1 β	Interleukin-1 beta
IPI	International Prognostic Index
IU	International unit
K	kappa
kD/kDa	Kilo-Dalton
LDH	Lactate dehydrogenase
LPL	Lymphoplasmacytic Lymphoma
MAb	Monoclonal antibody
MALT	Mucosa-associated lymphoid tissue
Max.	Maximum
MCL	Mantle cell lymphoma
MF	Mycosis fungoides

MHC	Major histocompatibility complex
Min.	Minimum
MM	Multiple Myeloma
MP	Metalloprotease
MRI	Magnetic resonance imaging
MUC	Mucin
MW	Molecular weight
MZL	Marginal Zone Lymphoma
n	Number
NA	Not applicable
NHLs	Non-Hodgkin's lymphomas
NK	Natural killer
NMZL	Nodal Marginal Zone Lymphoma
NOS	Not otherwise specified
NS	Non-significant
NSCLC	Non-small cell lung cancer
OS	Overall survival
p	Short arm of chromosome
P-	Negative predictive value
P+	Positive predictive value
PCR	Polymerase chain reaction
PET	Positron emission tomography
PLT	Platelet count
PMBL	Primary mediastinal large B-cell lymphoma
PRAD1	Parathyroid adenoma gene
Pre-B CLL	Precursor B-Cell Lymphoblastic Lymphoma
PS	Performance status
PSA	Prostate-specific antigen
PTH	Parathyroid hormone
PTH-RP	Parathyroid Hormone-Related Peptide
q	Long arm of chromosome
r	Correlation
R1	Reagent 1
R2	Reagent 2
REAL	Revised European-American Lymphoma classification
RNA	Ribonucleic acid
ROC	Receiver Operating Characteristic

S	Significant
SCC	Squamous cell carcinoma
SD	Standard deviation
SEA	Sea urchin sperm, Enterokinase, and Agrin
SELDI	Surface-enhanced laser desorption ionization
SLL/CLL	Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
SMZL	Splenic Marginal Zone Lymphoma
Sn	Sensitivity
Sp	Specificity
SS	Sézary syndrome
SVC	Superior vena cava
t	Translocation
TCR	T-cell receptor
TdT	Terminal deoxyribonucleotidyl transferase
TKD	Tyrosine kinase domain
T-LBL/T-ALL	T-cell lymphoblastic lymphoma/leukemia
TLC	Total leukocytic count
TN	True negative
TNF- α	Tumor necrosis factor alpha
TP	True positive
TP53	Tumor suppressor gene p53
TSGF	Tumor specific growth factor
ULN	Upper limit of normal
VEGF	Vascular endothelial growth factor
WHO	World Health Organization

List of Tables

<i>Table No</i>	<i>Title</i>	<i>Page</i>
1.	Summary of the possible causes of non-Hodgkin's lymphoma	6
2.	Ann Arbor staging classification and the Cotswold's modifications	13
3.	Good and poor prognostic factors for non-Hodgkin's lymphoma	15
4.	Good and poor prognostic factors for follicular lymphoma	17
5.	Key features of small B-cell lymphomas	31
6.	Key features of DLBCL variants and subtypes	34
7.	Key features of the most common T-cell lymphomas.....	46
8.	Evaluation of a new patient with non-Hodgkin's lymphoma	50
9.	Immunophenotypes of some common B-cell lymphomas	51
10.	Gene rearrangements in subtypes of non-Hodgkin's lymphoma	52
11.	Malignant disease associated with individual serologic tumor markers	66

<i>Table No</i>	<i>Title</i>	<i>Page</i>
12.	Ectopic tumor markers	68
13.	Clinical characteristics of patient group	120
14.	Age and quantitative laboratory data of patient group	121
15.	Qualitative laboratory data of patient group	121
16.	Age and laboratory data of control group	122
17.	Statistical comparison between patient group and control group regarding LDH, β_2 microglobulin and CA125	122
18.	Statistical comparison between males and females regarding LDH, β_2 microglobulin and CA125	123
19.	Statistical comparison between patients without night sweats and patients with night sweats regarding LDH, β_2 microglobulin and CA125	123
20.	Statistical comparison between patients without weight loss and patients with weight loss regarding LDH, β_2 microglobulin and CA125	124
21.	Statistical comparison between patients without hepatomegaly and patients with hepatomegaly regarding LDH, β_2 microglobulin and CA125	124

<i>Table No</i>	<i>Title</i>	<i>Page</i>
22.	Statistical comparison between patients without splenomegaly and patients with splenomegaly regarding LDH, β_2 microglobulin and CA125	125
23.	Statistical comparison between patients with no bone marrow infiltration and patients with bone marrow infiltration by bone marrow trephine biopsy regarding LDH, β_2 microglobulin and CA125	125
24.	Statistical comparison between patients with non-DLBCL and patients with DLBCL on lymph node biopsy regarding LDH, β_2 microglobulin and CA125...	126
25.	Statistical comparison between patients with low IPI and patients with high IPI regarding LDH, β_2 microglobulin and CA125	126
26.	Statistical comparison between control group and patients with low IPI regarding LDH, β_2 microglobulin and CA125	127
27.	Statistical comparison between control group and patients with high IPI regarding LDH, β_2 microglobulin and CA125	127
28.	Statistical comparison between newly diagnosed patients and patients on treatment regarding LDH, β_2 microglobulin and CA125	128